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Abstract: 
 
 
 
A critical challenge in the study of botanical natural products is the difficulty of identifying 
multiple compounds that may contribute additively, synergistically, or antagonistically to 
biological activity. Herein, it is demonstrated how combining untargeted metabolomics with 
synergy-directed fractionation can be effective toward accomplishing this goal. To demonstrate 
this approach, an extract of the botanical goldenseal (Hydrastis canadensis) was fractionated and 
tested for its ability to enhance the antimicrobial activity of the alkaloid berberine (4) against the 
pathogenic bacterium Staphylococcus aureus. Bioassay data were combined with untargeted 
mass spectrometry-based metabolomics data sets (biochemometrics) to produce selectivity ratio 
(SR) plots, which visually show which extract components are most strongly associated with the 
biological effect. Using this approach, the new flavonoid 3,3′-dihydroxy-5,7,4′-trimethoxy-6,8-
C-dimethylflavone (29) was identified, as were several flavonoids known to be active. When 
tested in combination with 4, 29 lowered the IC50 of 4 from 132.2 ± 1.1 μM to 91.5 ± 1.1 μM. In 
isolation, 29did not demonstrate antimicrobial activity. The current study highlights the 
importance of fractionation when utilizing metabolomics for identifying bioactive components 
from botanical extracts and demonstrates the power of SR plots to help merge and interpret 
complex biological and chemical data sets. 
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Article: 
 
In traditional and modern alternative health care practices, botanical extracts are employed 
frequently for medicinal purposes as complex mixtures. The claim is often made that such 
mixtures are more effective than their constituents in isolation due to additive or synergistic 
interactions among compounds.(1−4) However, the identification of the chemical constituents 
responsible for the observed activity of complex extracts remains a challenging pursuit. 
 
The traditional approach to identify active compounds from botanical mixtures, bioassay-guided 
fractionation, is highly effective for studying natural product mixtures when the activity can be 
traced to single, highly potent active compounds. Unfortunately, it is more difficult to effectively 
employ bioassay-guided fractionation when the activity of the mixture results from multiple 
compounds with low potency. Recently, a modification of the bioassay-guided fractionation 
approach designed to aid in the identification of multiple active compounds in a mixture, 
“synergy-directed fractionation”, was developed.(5) With synergy-directed fractionation, a 
botanical extract is fractionated and the resulting fractions are tested for activity in combination 
with a known active constituent of the original extract.(5) This approach was shown to be 
effective for identifying synergists in Hydrastis canadensis L. (Ranunculaceae).(5) However, 
one of the limitations of synergy-directed fractionation is that this technique, like bioassay-
guided fractionation, is inherently biased toward the compounds that are most easily isolated. 
Even though the methodology focuses on the most active fractions for isolation efforts, these 
fractions are often so complex that it is not possible to isolate every compound that they contain. 
Characteristics such as the abundance of a given compound and/or its ease of separation typically 
guide the isolation process in the latter steps, rather than true biological activity. As a result, the 
“active” compounds identified may represent only a subset of those responsible for the activity 
of the original mixture. 
 
There has recently been a great deal of interest among the scientific community in the 
application of untargeted metabolomics to identify active mixture compounds.(6−12) With this 
approach, analytical methods (typically NMR or MS) are used to detect as many of the small 
molecules in a mixture as possible (the “metabolome”), without bias toward which are 
chemically or biologically interesting. For metabolomics data to be employed for identification 
of active mixture components, it is necessary to collect metabolite profiles and corresponding 
biological assay data for a series of mixtures. Statistical methods are then applied to correlate 
chemical profile to bioactivity, a process that has been termed “biochemometrics”.(13) 
 
In theory, biochemometrics has the potential to overcome some of the aforementioned 
limitations of bioassay-guided fractionation and to provide a more comprehensive representation 
of which compounds are responsible for the activity of a botanical extract. However, the inherent 
complexity of botanical extracts makes the data analysis aspects of the biochemometrics 
challenging when employed for this purpose. Several data analysis approaches have been 
employed to address this challenge. Inui et al. applied Pearson correlation coefficients to 2D 
orthogonal chromatography and incorporated biological data to identify mass spectral ions for 
which variance positively correlated with biological activity.(9) Pearson correlation coefficients 
are a univariate statistical approach to measure the strength of linear correlation between single 
pairs of variables (i.e., concentration and biological activity) in isolation. A limitation of this 
approach is that the Pearson correlation does not consider potential interactions between 
variables and is easily skewed by such outliers.(14) In contrast, Kulakowski et al. utilized 
unsupervised principal component analysis (PCA) and supervised orthogonal partial least-
squares discriminatory analysis (OPLS-DA) to correlate bioactivity to LC-MS profiles.(6) PCA 
can be used to group samples based upon covariance, so fractions with similar profiles will be 
clustered, while others will be in a different location in the PCA scores plot. PCA is useful for 
describing chemical differences among samples, but does not provide insight into which of the 
constituents of these samples are biologically active. OPLS-DA allows for the incorporation of 
biological data, which were in this case binary classifications, i.e., active/nonactive 
fractions.(6) OPLS-DA plots appear similar to PCA plots, and an OPLS-DA model can be 
represented as an S-plot, where each axis represents the covariance and correlation loading 
variables.(15) Biomarkers with intensities that correlate and covary with the bioactivity appear 
the furthest from the origin.(6,7) An important limitation of this approach is that covariance 
increases with increased concentration of a constituent, such that the approach is biased toward 
selection of abundant constituents at the expense of low-abundant compounds that may have 
high biological activity.(12) 
 
Selectivity ratio plots are derived from the ratio of explained and residual variance on a single 
multivariate component that incorporates bioactivity information in the multivariate PLS model 
and can thus be employed to identify mixture components that are most strongly associated with 
an observed biological effect independent of concentration.(12) Selectivity ratios were first 
applied to identifying biomarkers of diseases from complex cerebrospinal fluid data 
sets.(16) Recently, the applicability of this biochemometrics approach using selectivity ratios to 
identify biologically active compounds from fungal extracts was demonstrated.(12) As of yet, 
this approach has not, however, been applied to botanical extracts. Compared to botanicals, fungi 
produce relatively simple mixtures of chemical compounds. Thus, it is expected that the 
application of this biochemometric approach to botanical extracts, which are more complex, 
would be more challenging. Furthermore, an added challenge with botanical extracts is that their 
greater complexity means that synergistic, additive, or antagonistic interactions are more likely 
to occur.(17) 
 
With the study presented herein, an approach combining biochemometrics with synergy-directed 
fractionation to identify active compounds and/or synergists from a botanical extract was 
developed. As a case study, the botanical H. canadensis was selected, which is used widely in 
alternative healthcare practices for the treatment of infections.(18,19) Activity against the 
common Gram-positive bacterium Staphylococcus aureus was evaluated, given that H. 
canadensis has previously been shown to possess activity against this pathogen.(20) 
 
Chart 1. 
 
 
Earlier studies with H. canadensis have identified several compounds that interact synergistically 
to effect antimicrobial activity; thus, this botanical serves as a useful test case for evaluating a 
new approach to identify synergists. Specifically, H. canadensis is known to contain a number of 
flavonoids (sideroxylin, 6-desmethyl-sideroxylin, 8-desmethyl-sideroxylin, 3,5,3′-trihydroxy-
7,4′-dimethoxy-6,8-di-C-dimethylflavone, 5,4′-dihydroxy-6-C-methyl-7-methoxyflavone, 5,4′-
dihydroxy-6,8-di-C-methyl-7-methoxyflavone, 6,8-di-C-methylluteolin-7-methyl ether, and 6-C-
methylluteolin-7-methyl ether [1–3, 5–9, respectively]), alkaloids, and other compounds 
(berberine, oxyberberine, berberastine, tetrahydroberberastine, canadine, canadaline, canadinic 
acid, 8-oxocanadine, β-hydrastine, hydrastidine, hydrastinine, oxyhydrastinine, 
noroxyhydrastinine, chilenine, 4′,5′-dimethoxy-4-methyl-3′-oxo(1,2,5,6-tetrahydro-4H-1,3-
dioxolo-[4′,5′:4,5]-benzo[1,2-e]-1,2-oxazocin)-2-spiro-1′-phthalan, 8-oxotetrahydrothalifendine, 
corypalmine, isocorypalmine, tetrahydropalmatine, and 3,4-dimethoxycarbonylbenzoic acid 
[4, 10–28]) with diverse structures.(21,22) Recently, it was shown that the flavonoids from H. 
canadensis sideroxylin (1), 6-desmethyl-sideroxylin (2), and 8-desmethyl-sideroxylin (3) 
enhance synergistically the antimicrobial activity of the alkaloid berberine (4) against S. 
aureus by acting as bacterial efflux pump inhibitors.(5) In a separate report, the flavonoid 3,5,3′-
trihydroxy-7,4′-dimethoxy-6,8-C-dimethylflavone (5) was also shown to act as an efflux pump 
inhibitor.(21) H. canadensis also contains several alkaloids that do not act as efflux pump 
inhibitors (13, 17, 24) or possess biologically relevant antimicrobial activity (10, 13–
15, 17, 24, 25).(21−31) Finally, a number of compounds have also been identified from H. 
canadensis for which biological activity has not been evaluated 
(7, 11, 12, 16, 18, 19, 23, 27).(21,30,32−37) Relying on existing knowledge about the chemistry 
and biological activity of H. canadensis, the goal with this investigation was to apply synergy-
directed fractionation combined with biochemometric data analysis to an H. canadensisextract. 
The ultimate objective of these studies was to evaluate the effectiveness of this methodology to 
identify known active constituents and/or identify new bioactive compounds from a botanical 
extract. 
 
Results and Discussion 
 
 
Figure 1. Minimum inhibitory concentration (MIC) of each fraction + berberine against S. aureus. Berberine was tested alone, and 
berberine + piperine served as the positive control. Each fraction was combined at a constant concentration of fraction (75 μg/mL) 
with varying concentrations of berberine. (A) First-stage normal-phase fractions, where GS-4 lowered the MIC the greatest amount. 
(B) Secondary fractionation of GS-4 via normal-phase chromatography yielded fractions GS-4-1 through 16, and the fractions 
therefrom were also tested in combination with berberine. (C) This process was repeated for stage 3, which was prepared using 
reversed phase chromatographic separation of GS-4-4. Data from which the MIC values were derived, with its associated uncertainty 
and error bars, can be found in Figure S2 (Supporting Information). Note that error bars are not included in this figure because MIC is 
defined as the concentration of test compound necessary to completely inhibit bacteria growth, which is the same concentration for all 
three biological replicates. 
 
Figure 2. LC-MS chromatograms (collected with ultraperformance liquid chromatography coupled to a Q-Exactive Orbitrap mass 
spectrometer) of a series of H. canadensis extract fractions. (A) Positive-ion electrospray mass spectrometry chromatogram of the 
crude extract after liquid–liquid partitioning. (B) The most active fraction (GS-4) of the crude extract shown in A after separation with 
flash chromatography over silica gel using a hexane–chloroform–methanol gradient (stage 1 separation). GS-4 was further 
fractionated using a second stage of flash chromatography over silica gel with a hexane–ethyl acetate–methanol gradient with GS-4-4 
being the most active (C). GS-4-4-2 generated with stage 3 fractionation (using reversed-phase preparative HPLC with a water–
acetonitrile gradient) (D). (E–H) The same H. canadensis extract and fractions analyzed using LC-MS in the negative-ion mode. 
Arrows represent the region of the chromatogram in which a given ion corresponding to a known constituent of H. canadensis 
(indicated by compound numbers) could be detected. Compounds 1–7, 10, 13, 16, 17, 20–24, and 28 were identified by comparison of 
retention time and fragmentation with authenticated standards,(20) while compounds 8, 9, 11, 12, 14, 15, 18, 19, and 25–27 were 
tentatively identified by comparison of accurate mass and molecular formula with literature reports.(22,24,27,29,33,36,37) 29 is a new 
flavonoid that was isolated and identified based on NMR and MS data as part of this report. Red dotted arrows represent alkaloids and 
other compounds, while green dashed arrows represent flavonoids. In cases where a specific peak is not apparent in the 
chromatogram, the ion was identified based on mass spectrometric data. 
 
For this study, a leaf extract was chosen for evaluation because H. canadensis leaves have a 
higher flavonoid content than the roots. Leaf material also tends to be highly complex; therefore, 
it was anticipated that reducing the complexity by fractionating an H. canadensis extract would 
be necessary to provide useful data for biochemometrics analysis. To determine how much 
fractionation would be necessary, the results of biochemometric analysis were compared on a 
sequential series of H. canadensis extract fractions and subfractions with decreasing complexity. 
Specifically, the original extract was subjected to liquid–liquid partitioning initially and then 
separated chromatographically in a series of four stages (Figure S1, Supporting Information). 
The most active fraction from each stage was moved forward for further separation. To evaluate 
biological activity of the fractions produced by each stage of separation, S. aureus cultures were 
treated with varying concentrations of the alkaloid berberine (a known antimicrobial constituent 
of H. canadensis) in combination with constant concentrations of the H. canadensis fractions. 
The minimum concentration of berberine necessary to completely inhibit bacterial growth 
[minimum inhibitory concentration (MIC)] was compared in the presence of each H. 
canadensis fraction. With this approach, fractions containing compounds that enhance the 
antimicrobial activity of berberine (synergistically or additively) will lower the effective MIC of 
berberine against S. aureus (Figure 1). Metabolite profiles of the fractions from each stage of 
separation were collected using high resolving power mass spectrometry (Figure 2), as described 
in the Experimental Section, and biochemometric analyses (using selectivity ratio plots) were 
employed to integrate the metabolite profile data with the results of the bioassay data (Figure 3). 
 
 
Figure 3. Selectivity ratio plots for first, second, and third stages of fractionation [(A), (B), and (C), respectively] with green dashed 
arrows representing flavonoids and red dotted arrows representing alkaloids and other known constituents of H. canadensis. The 
signals of flavonoids and the alkaloid berberine, all known to be or predicted to be active in the assay being used, are not prominent in 
first-stage fractionation (A) and second-stage fractionation (B). (C) Third-stage fractionation yielded seven flavonoids 
(1, 2, 3, 5, 6, 8, 29) and three alkaloids (10, 22, 23) with negative selectivity ratios (suggesting these compounds to contribute 
additively or synergistically to antimicrobial activity). The bar labeled 29* represents the 13C isotope of 29. The identities and 
activities of compounds represented by other prominent peaks are not known. Selectivity ratio plots were generated by integrating the 
bioassay data and chemical profile for each stage of fractionation separately. (Data from multiple stages of fractionation were not 
combined.) 
Biochemometrics to Guide Isolation 
 
The H. canadensis extract and multiple fractions therefrom demonstrated the desired biological 
effect, an ability to enhance the antimicrobial activity of berberine (i.e., reduce its MIC value) 
against S. aureus (Figure 1; Figure S2, Supporting Information). Importantly, the positive 
control, a known efflux pump inhibitor(38) (piperine), also reduced the MIC of berberine. From 
the first stage of fractionation, the strongest activity was observed for fraction 4, which reduced 
the MIC of berberine from 150 μg/mL to 18.8 μg/mL (Figure 1A). Thus, GS-4 was selected as 
starting material for subsequent fractionation, yielding a series of subfractions, from among 
which fraction GS-4-4 demonstrated the best activity (Figure 1B). This process was repeated to 
produce a subfraction set where GS-4-4-2 possessed the most potent activity in combination with 
berberine (Figure 1C) (see Figure S2, Supporting Information for fraction labeling scheme). 
 
A necessary first step in the application of biochemometrics to identify active mixture 
components is that the compounds must be detectable by the analytical approach employed (in 
this case, LC-MS). Thus, the data resulting from LC-MS analysis of the H. canadensis extract 
(Figure 2A and F) were inspected to determine whether known H. canadensis constituents were 
detectable. Indeed, a number of flavonoids and alkaloids known to be present in H. 
canadensis were identifiable (Figure 2) based on LC-MS data (1–28) or by isolation and 
structure elucidation (29). Pursuit of the most biologically active fractions (Figure 1) throughout 
the isolation process resulted in selection of fractions with greater flavonoid abundance with 
each successive stage of isolation (Figure 2). This result is to be expected given that flavonoids 
are known to enhance the antimicrobial activity of alkaloids,(4,39−41) and the biological assay 
used as a basis for this study was enhancement of antimicrobial activity of the alkaloid berberine. 
 
A known limitation of the application of mass spectrometric analysis to evaluate chemical 
composition of mixtures is the selectivity of the technique. Relative abundances in LC-MS 
chromatograms reflect what is most easily ionizable rather than what is truly present in the 
mixture at highest concentration. Inspection of the data resulting from analysis of the H. 
canadensis extract evaluated herein illustrates this limitation. Alkaloids, which are easily 
protonatable, are highly amenable to analysis with electrospray ionization mass spectrometry in 
the positive-ion mode. Thus, positive-ion mode analysis of the H. canadensis resulted in 
chromatograms dominated by alkaloids (Figure 2A–D), at least in the earlier stages of 
fractionation before these alkaloids were separated into inactive fractions. Conversely, data 
collected in the negative-ion mode were dominated by flavonoids, which are more easily 
deprotonated (Figures 2E–H). It is important when conducting metabolomics profiling of a 
botanical extract to collect data in both ionization modes. Additionally, one must always be 
cognizant of the possibility that certain important mixture components may not be detected and 
that the relative abundances in LC-MS chromatograms may not reflect the actual relative 
abundances in the mixture. 
 
An advantage of LC-MS is that it enables the simultaneous detection of multiple constituents that 
have the same chromatographic retention time. This phenomenon is most apparent 
from Figure 2A, where eight goldenseal compounds were found within one chromatographic 
peak that eluted around 4.1 min. The peak shown represents the relative abundance of the most 
abundant ion during this time span, not the collective signal of all ions. For metabolomics 
analysis, these chromatograms are deconvoluted (using MZmine) to identify multiple retention 
time–mass pairs, even those that coelute. Thus, all detectable ions (above a set noise threshold) 
are compared with bioactivity and correlations are determined, not just those that are apparent in 
the base peak chromatograms. 
 
The selectivity ratio plots shown in Figure 3 are the output of biochemometric analysis 
combining the data obtained from biological evaluation (Figure 1) and chemical evaluation 
(Figure 2) of the H. canadensis extract and fractions. To generate these plots, a series of unique 
marker ions (m/z–retention time pairings) obtained from analysis of the LC-MS data were used 
from each stage of fractionation (595, 612, and 149 ions for stages one through three, 
respectively). The selectivity ratio plots represent the m/z of each ion detected on the x-axis and 
the selectivity ratio (the ratio of explained variance to residual variance, which is derived from 
the PLS model) on the y-axis for each independent stage of fractionation. Since the biological 
assay data used for this analysis was growth inhibition, the ions with the most negative (pointing 
down in Figure 3) selectivity ratios represent those associated with the desired biological effect 
(antimicrobial activity). Ions with very small selectivity ratios or positive selectivity ratios (either 
no bar or pointing up, respectively, in Figure 3) are not expected to have synergistic or additive 
activity when combined with berberine. 
 
Selectivity ratio plots (Figure 3) have the advantage over LC-MS or LC-UV chromatograms in 
that the size of bars is representative of constituents possessing the desired effect (biological 
activity) rather than unrelated effects such as high concentration, ionizability, or molar 
absorptivity. Thus, in theory, selectivity ratio plots should be extremely helpful for guiding the 
isolation of bioactive compounds. It is worth mentioning here that scientists engaged in bioassay-
guided fractionation typically do make decisions about which fractions to pursue for isolation 
based on which fractions possess the greatest biological activity. The challenge, of course, is in 
deciding which components of these fractions to isolate. Typically, a researcher would compare 
the chromatographic profile of active and inactive fractions to determine which peaks differ 
between them. However, when hundreds or thousands of components are present, and when 
more than one fraction is being compared, it becomes very difficult to do this with simple visual 
inspection. Also, visually one tends to be biased by the tallest peaks of those most distinctly 
separated from other peaks (even though these may be neither the most abundant nor the most 
active ions). The use of selectivity ratio plots improves the efficiency of the process by 
comparing all of the detected ions (both active and inactive) and corresponding peak areas of all 
fractions in a given stage of separation with their associated biological activity. The result is a 
quantitative value (the selectivity ratio) that describes how well each ion is associated with the 
observed biological activity independent of concentration bias (again, assuming that the ion is 
detected by the analytical method being employed). 
 
How Much Fractionation Is Necessary? 
 
It is important to recognize an inherent limitation of the biochemometric approach, in that 
associations between activity and chemical composition are correlative, rather than causal. It is 
always possible that ions identified as bioactive in a selectivity ratio plot may covary in fractions 
with active ions, but may not possess activity themselves. Such ions would represent false 
positives. The likelihood of observing such false positives increases as the chemical complexity 
of the fractions evaluated increases. Conversely, it is also possible that particular bioactive 
mixture components might go undetected by the analytical approach used or be at a 
concentration too low to register a biological effect (i.e., antimicrobial activity). Such a scenario 
would result in a false negative. Using H. canadensis as a test case, one of the goals of this study 
was to evaluate empirically the likelihood of occurrence of such false positives and false 
negatives by comparing the results of biochemometric analysis on three different stages of 
fractionation (Figure 3). 
 
Stage 1 fractions were subjected to subsequent biochemometric analysis, and multivariate partial 
least-squares (PLS) modeling of the combined bioassay and spectral data matrix yielded the 
selectivity ratio plot shown in Figure 3A. The selectivity ratio plot based on the first stage of 
separation indicated several false negatives. Although four confirmed active flavonoids 
(compounds 1–3 and 5) and the alkaloid berberine (4) were detected among the ions from this 
first stage of fractionation (Figure 2A), none of these ions were highlighted as major active 
constituents in the selectivity plot (i.e., ions with large negative selectivity ratios). The 
flavonoids sideroxylin (1), 6-desmethyl-sideroxylin (2), and 8-desmethyl-sideroxylin (3) were 
detected in the most active fraction from the first stage of fractionation (GS-4, which lowered the 
MIC of berberine from 150 μg/mL to 18 μg/mL), but did not display the expected large, negative 
selectivity ratios. This failure to identify the active flavonoids among other mixture components 
can be explained by the high level of complexity of these fractions and inability to resolve active 
and inactive compounds. These findings demonstrate an inherent limitation of metabolomic 
studies in which investigators attempt to identify active compounds from mixtures without prior 
fractionation. 
 
Notably, a number of ions were identified in this first-stage fractionation with highly negative 
selectivity ratios (Figure 1A). It is unclear whether these ions (for which activity and structure 
are unknown) constitute a series of false positives, or whether they are truly active but hitherto 
unidentified constituents of H. canadensis. The data do suggest that at least one of the ions 
identified in Figure 1A is a false negative. The ion with the most negative SR (m/z 527.3156 [M 
+ H]+) was most abundant (relatively, based upon MS signal) in fraction GS-8, which did not 
prove to be an active fraction (Figure 1B). This highlights the potential for false positives when 
using this biochemometrics approach and further supports the assertion that some fractionation is 
required to obtain useful selectivity ratio plots. In addition, ions that appear to be “active” in the 
stage 1 fractions are not present in later-stage selectivity ratio plots, which indicates that they are 
false positives and not true antimicrobials or antimicrobial synergists. 
 
GS-4 was chosen for further purification based upon its lowering of the MIC of berberine from 
150 μg/mL to 18 μg/mL (Figure 1A). The resulting 16 fractions, excluding GS-4-1, lowered the 
MIC of berberine to values ranging between 2.34 and 75 μg/mL, and the resulting selectivity 
ratio plot is shown in Figure 3B. As with stage 1 fractions, the known flavonoid synergists (1–3) 
and the antimicrobial alkaloid berberine (4) were detected in these fractions. In this less complex 
series of stage 2 fractions, berberine (known to be active) displayed the expected negative 
selectivity ratio. However, the second stage of fractionation still failed to show activity for the 
known active flavonoids (1–3). Finally, as with the first-stage fractionation, several ions of 
unknown identity displayed large negative selectivity ratios. The possible biological activity of 
these ions was not further pursued, but could be the subject of future investigations. 
 
Fraction GS-4-4 was the most bioactive from the second stage of fractionation, decreasing the 
MIC of berberine from 150 μg/mL to 2.3 μg/mL (Figure 1B). The nine subfractions of GS-4-4 
were subjected to biochemometric analysis, resulting in the selectivity ratio plot shown 
in Figure 3C. Compounds 5 (m/z 359.1121 and 359.1122 [M + H]+) and 8 (m/z 329.1017 [M + 
H]+ and 327.0879 [M – H]−) had the third and fourth largest negative selectivity ratios, with the 
first and second largest negative selectivity ratios representing m/z 373.1279 [M + H]+ and its 13C 
isotope, respectively. This ion represented a compound not yet known to H. canadensis and was 
targeted for isolation. Additionally, chilenine (22) and 4′,5′-dimethoxy-4-methyl-3′-oxo(1,2,5,6-
tetrahydro-4H-1,3-dioxolo-[4′,5′:4,5]-benzo[1,2-e]-1,2-oxazocin)-2-spiro-1′-phthalan (23) were 
identified as potential active components based on biochemometric analysis of the third-stage 
fractions (Figure 3C). Chilenine has previously been reported as a constituent of H. canadensis, 
but its biological activity is unknown.(21) The data presented here suggest that it might possess 
antimicrobial activity (alone or in combination with berberine), a possibility that could be 
investigated in a future study. 
 
For the studies reported here, statistical analysis to compare chemical composition and biological 
activity was conducted separately for each stage of fractionation. The possibility of combining 
the bioassay and metabolomics data for all three stages of fractionation and analyzing as a single 
data set was also explored (data not shown), but the use of three stages in combination did not 
improve the ability to detect known active compounds. Previous reports suggest that the 
inclusion of mass spectrometric and biological data from multiple stages of fractionation can 
improve assignment of bioactive mixture compounds by increasing statistical power.(11,12) For 
these previous studies, however, natural product mixtures were derived from bacteria and fungi, 
which are chemically less complex than the botanical extracts evaluated here. It appears that in 
situations such as this one, where the initial fractions are extremely complex, the inclusion of 
these data sets in the overall analysis may be detrimental rather than helpful. 
 
Verification of Activity for a Compound Predicted to be Active Based on Biochemometrics 
 
Guided by the results of the biochemometric analysis (Figure 2C), 29 was isolated and identified 
as the new flavonoid 3,3′-dihydroxy-5,7,4′-trimethoxy-6,8-C-dimethylflavone (Figures S3–S7, 
Supporting Information). The isolated mass (0.84 mg) was insufficient for completing a full 
synergy assessment, so 29 was tested at a constant concentration (75 μg/mL or 201.4 μM) in 
combination with concentrations of berberine ranging from 0 to 100 μg/mL (297.5 μM) 
(Figure 4). The known efflux pump inhibitor piperine(38) was also included in this assay (at a 
constant concentration of 200 μM) as a positive control. 
 
Both piperine and 29 influenced the activity of berberine (Figure 4). The MIC of berberine alone 
was 238 μM, but in combination with piperine and 29, the MIC was lowered to 119 and 179 μM, 
respectively. When tested in combination with 29, the IC50 of berberine was lowered from 132.2 
± 1.1 μM to 91.5 ± 1.1 μM. Piperine demonstrated a similar activity, resulting in a lowered 
berberine IC50 of 72.3 ± 1.0 μM. These data suggest that 29 does, indeed, enhance the 
antimicrobial activity of berberine. Importantly, 29 alone at 402.8 and 201.4 μM demonstrated 
no antimicrobial activity (data not shown), suggesting that the increased efficacy of berberine in 
combination with 29 is due to synergy, not additivity. Thus, 29, which has no antimicrobial 
activity alone, potentiates the antimicrobial efficacy of berberine. The potency of 29 in 
combination with berberine is not high as that of the precursor fraction (GS-4-4-2, which 
lowered the MIC of berberine from 150 μg/mL to 4.68 μg/mL), which further supports that the 
activity of fraction GS-4-4-2 is due to the presence of multiple constituents, including 
compounds 1–3, 5, and 6. 
 
 
Figure 4. Dose–response curve of berberine ranging from 0 to 298 μM in combination with piperine (positive control, fixed 
concentration of 263 μM) and 29(fixed concentration of 200 μM). Error bars represent standard error (error bars are not visible for 
some data points because they are smaller than the point size). The expected shift to the left (increased potency) in the berberine dose–
response curves in the presence of both piperine and 29 was observed. Notably, 29 did not have any antimicrobial effect when tested 
individually at 200 and 400 μM, which suggests that the increased potency of berberine in combination with this compound is due to 
synergy and not additivity. 
 
Did Biochemometrics Improve the Synergy-Directed Fractionation Process? 
 
Previous work using synergy-directed fractionation on H. canadensis (without biochemometrics) 
resulted in the identification of three flavonoids (1–3) that synergistically enhanced the 
antimicrobial activity of berberine (4).(5) The application of biochemometrics enabled the list of 
putative active compounds to be increased to nine compounds. Specifically, based on the 
biochemometrics data for the third stage of fractions (Figure 3C), the flavonoids 1, 2, 3, 5, 8, 
and 29 and the alkaloids 10, 22, and 23 were all predicted to act as additives or synergists to the 
antimicrobial activity of berberine. How accurate were these predictions? Compounds 1–
3 and 5are known efflux pump inhibitors, as demonstrated in several previous 
studies.(5,21) Compound 8has not previously been evaluated for biological activity against S. 
aureus, but has been shown to have antimicrobial activity against Streptococcus 
mutans and Fusobacterium nucleatum.(22)Based upon its structural similarity to 1, which has 
one less hydroxy group at the C-3′ position, 8 is likely to be active as an efflux pump inhibitor. 
Compound 29 is a new compound, isolated as part of these studies, and demonstrated to increase 
synergistically the antimicrobial activity of berberine (Figure 4). It is likely that, like other 
flavonoids, the activity of 29 is due to bacterial efflux pump inhibition, although the efflux pump 
inhibitory activity of this compound was not evaluated here. Alkaloid 10 was shown previously 
in the literature to not have antimicrobial activity against S. aureus when tested at 25.6 μg using 
a disk diffusion assay.(31) Further studies would be needed to show if 10 is antimicrobial under 
other conditions and if it exhibits synergy in combination with berberine. Similarly, 
alkaloids 22 and 23 have no reported biological activity, and their activity as synergists or 
antimicrobials could be confirmed with further studies. As a side note, alkaloid 23was found to 
be a product of β-hydrastine-N-oxide under reflux conditions and is likely present here as an 
isolation artifact.(21,42) 
 
A major challenge faced by any investigator conducting bioassay-guided fractionation is to 
decide which mixture components to target for isolation. The magnitude of this challenge is 
illustrated by the sheer number of ions detectable with mass spectrometric analysis of a botanical 
extract. In this study, a total of 595, 612, and 149 features were detected (above the selected 
signal threshold) in the first, second, and third stage of H. canadensis fractionation, respectively. 
When addressing this challenge, the inclination of the investigator is to focus on the most 
detectable ions (which may or may not be the most abundant) in the most biologically active 
fraction. The application of biochemometrics to guide isolation helps reduce that inherent bias. 
Relevant to the study here, 29 was identified for isolation in this project because it has the largest 
negative selectivity ratio in the third-stage fractionation. Notably, this compound was not the ion 
detected with highest abundance in the most active fraction (GS-4-4-2, Figure 2D and H). Visual 
inspection of the data from that fraction would have led the observer to overlook 29 and instead 
focus on 1, 2, and 3, which appear to be highly abundant and have already been isolated and 
identified as synergists as part of a previous study. Ultimately, isolation and subsequent NMR 
structure elucidation will always be needed to confirm absolute configuration and solve 
structures of unknown compounds. Furthermore, given the correlative rather than causal nature 
of activity predictions based on biochemometric data analysis, isolation and biological activity 
evaluation are very necessary as a means of validation. As demonstrated here, the use of 
biochemometrics to integrate bioassay data with mass spectrometric metabolite profiles can help 
guide the isolation process toward constituents that may possess relevant biological activity. 
Importantly, however, as was the case in this study, the complexity of botanical extracts may 
necessitate several stages of fractionation to simplify the mixture before biochemometric 
analysis yields useful results. 
 
Experimental Section 
 
General Experimental Procedures 
 
Extracts were suspended in 1:1 MeOH–dioxane (LC/MS grade, Fisher Scientific, Hampton, NH, 
USA) at either 1 or 0.1 mg/mL and subjected to ultraperformance liquid chromatography tandem 
mass spectrometry (UPLC-MS/MS) analysis via a Waters Acquity UPLC with an Acquity UPLC 
column (BEH C18, 1.7 μm, 2.1 × 50 mm, Waters Corporation, Milford, MA, USA) and a Thermo 
Q-Exactive Plus orbitrap mass spectrometer with heated electrospray ionization (Thermo Fisher 
Scientific, Milford, MA, USA). Analysis was performed at a flow rate of 0.3 mL/min using the 
following binary solvent system with A consisting of water with 0.1% formic acid additive and 
solvent B consisting of acetonitrile with 0.1% formic acid additive (LC/MS grade, Fisher 
Scientific). The gradient was as follows: 95:5 (A:B) from 0 to 1 min, increasing to 90:10 (A:B) 
from 1 to 2 min, 80:20 (A:B) from 2 to 3 min, 60:40 (A:B) from 3 to 4 min, 70:30 (A:B) from 4 
to 5 min, 0:100 (A:B) from 5 to 6 min and held from 6 to 7 min, 95:5 (A:B) from 7 to 8 min and 
held from 8 to 9 min. The Thermo Q-Exactive Plus was operated in both positive and negative 
polarities using the following settings: spray voltage, 3.7 kV; capillary temperature, 350 °C; 
sheath gas, 25; auxiliary gas, 5; S-lens RF level, 50. Known constituents of goldenseal were 
listed in an inclusion list for fragmentation via high-energy collision-induced dissociation (HCD) 
and used for tentative identification based upon matching retention time, accurate mass, and 
accurate mass fragments with isolated standards (compounds 1–7, 10, 13, 16, 17, 20–24, 
and 28).(20) Compounds without standards (8, 9, 11, 12, 14, 15, 18, 19, and 25–27) were 
identified tentatively by comparison of accurate mass and molecular formula with literature 
reports.(21,23,26,28,32,35) Data were visualized using Xcalibur (v. 2.3.26, Thermo Fisher 
Scientific). Phenomenex Gemini-NX C18analytical (5 μm; 250 × 4.6 mm) and preparative (5 μm; 
250 × 21.2 mm) and Phenomenex Luna PFP(2) 100A analytical (5 μm; 150 × 4.6 mm) and 
preparative (5 μm; 250 × 21.2 mm, Phenomenex, Torrance, CA, USA) columns were used on a 
Varian Prostar HPLC system equipped with Prostar 210 pumps and a Prostar 335 photodiode 
array detector (Agilent Technologies, Santa Clara, CA, USA), with data collected and analyzed 
using Galaxie Chromatography Workstation software (version 1.9.3.2, Agilent Technologies). 
Flash chromatography was performed on a Teledyne ISCO CombiFlash Rf 200 (Teledyne-Isco, 
Lincoln, NE, USA) using Gold silica columns (330, 120, and 40 g columns) and monitored by 
UV and evaporative light-scattering detectors. 1D and 2D NMR spectra were recorded using a 
JEOL ECA-500 NMR spectrometer operating at 400 MHz for 1H and 100 MHz for 13C (JEOL, 
Peabody, MA, USA) or an Agilent 700 MHz NMR spectrometer (Agilent Technologies) 
equipped with a cryoprope, operating at 175 MHz for 13C. NMR data were visualized using 
MestReNova (v 11.0.4, Mestrelab Research, Santiago de Compostela, Spain). IC50 values were 
calculated using a four-parameter logistic standard curve analysis function in SigmaPlot (v.13, 
Systat Software, San Jose, CA, USA). All chemicals used unless otherwise stated were ACS 
grade and obtained from Fisher Scientific. 
 
Plant Material 
 
Hydrastis canadensis bulk leaf material was collected in June 2014 from William Burch in 
Hendersonville, North Carolina (NC, N 35°24.277′, W 082°20.993′, 702.4 m elevation). The 
plants were cultivated in their natural environment, a hardwood forest understory, and were a 
year old at the time of harvest. A voucher specimen for this H. canadensis plot has been 
deposited at the Herbarium of the University of North Carolina at Chapel Hill (NCU583414) and 
authenticated by Dr. Alan S. Weakly. Samples were dried at room temperature until crisp before 
extraction. 
 
Extraction and Isolation 
 
Dried aerial plant portions were ground mechanically using a Wiley mill standard model no. 3 
(Arthur H. Thomas Co., Philadelphia, PA, USA) with a 2 mm mesh size and percolated in 
MeOH overnight three times. The MeOH extract was concentrated in vacuo before liquid–liquid 
extraction. The extract was defatted by partitioning between hexane and 10% aqueous MeOH 
(1:1). The dried aqueous MeOH was partitioned further between 4:5:1 EtOAc–MeOH–H2O, and 
the organic layer was washed with 1% saline solution to remove hydrosoluble tannins. The 
fractionation scheme is provided as Supporting Information. The first stage of normal-phase 
flash chromatography (330 g Gold silica gel column) was performed in two batches (58.49 g 
total) and conducted at a 200 mL/min flow rate with a 42.7 min hexane–CHCl3–MeOH gradient. 
The most active fraction from the first-stage separation (fraction 4, ∼10 g) was subjected to a 
second stage of normal-phase flash chromatography (120 g Gold silica gel column and 40 g Gold 
silica gel column) and conducted at flow rates of 85 and 40 mL/min, respectively, with 57.6 and 
33.4 min hexane–EtOAc–MeOH gradients, respectively. The most active fraction from the 
second-stage separation (subfraction 4, ∼290 mg) was purified using reversed-phase HPLC with 
a Phenomenex Gemini-NX column at a 21.4 mL/min flow rate in three batches. A CH3CN–H2O 
with 0.1% formic acid gradient was employed, which was held at 30:70 for 5 min, increased to 
60:40 from 5 to 10 min, increased to 0:100 from 10 to 25 min, and held at 100:0 from 25 to 40 
min. It was determined that the ion of interest via biochemometric analysis of the third stage of 
fractionation, m/z373.1279 [M + H]+, had the greatest relative abundance in fraction GS-4-5 and 
was therefore used for isolation. GS-4-5 was subjected to reversed-phase HPLC with a 
preparative Luna PFP column at a 21.4 mL/min flow rate. A CH3CN–H2O with 0.1% formic acid 
gradient was employed that increased from 35:65 to 50:50 over 8 min, held at 50:50 from 8 to 30 
min, increased to 100:0 from 30 to 35 min, and then held at 100:0 from 35 to 55 min. Fractions 
41 through 43 were recombined and subjected to reversed-phase HPLC with an analytical Luna 
PFP column at 1 mL/min. A MeOH–H2O with 0.1% formic acid gradient was employed where 
the solvent composition increased from 72:28 to 76:24 over 30 min and increased to 100:0 from 
30 to 40 min. Fractions were collected manually into vials based upon UV absorption and LC-
MS traces. One last stage of purification was performed to achieve 95.4% purity via UV (254 
nm) using a Gemini analytical column with a CH3CN–H2O with 0.1% formic acid solvent 
system at 1 mL/min, where the gradient increased from 10:90 to 100:0 over 55 min and was held 
at 100:0 from 55 to 60 min. Compound 29 had a final yield of 0.84 mg (0.0014% of 58.49 g of 
EtOAc extract). 
 
3,3′-Dihydroxy-5,7,4′-trimethoxy-6,8-C-dimethylflavone (29): 
 
yellow solid; UV (MeOH) λmax (log ε) 254 (4.42) 363 (4.26) nm; 1H NMR (DMSO, 500 
MHz, Figure S3, Supporting Information) and 13C NMR (DMSO, 175 MHz, Figure S4, 
Supporting Information), see Table 1; HRESIMS m/z 373.1279 [M + H]+ (calcd for C20H21O7, 
373.1287). Because there were no HMBC correlations for the hydroxy protons attached to C-3 
and C-3′, OH-3′ was assigned based upon literature precedent that hydroxy group protons 
attached to aromatic rings have sharper peaks than those that are not.(43) 
 
Antimicrobial Assays 
 
Minimum inhibitory concentrations were evaluated per the terms outlined by the Clinical 
Laboratory Standards Institute(44) against wild-type Staphylococcus aureus (SA1199).(45) A 
single colony inoculum was grown to log phase in Müeller Hinton broth and adjusted to a final 
assay concentration of 1.0 × 105 CFU/mL based on absorbance at 600 nm (OD600). The negative 
control consisted of 2% glycerol and 2% DMSO in broth (vehicle), and the known antimicrobial 
compound berberine(46) served as the positive control. Triplicate wells were prepared with all 
treatments and controls. Duplicate plates were made without bacteria for background absorbance 
subtraction. OD600 was read after 18 h at 37 °C using a Synergy H1 microplate reader (Biotek, 
Winooski, VT, USA). The MIC was defined as the concentration at which no statistically 
significant difference was observed between the negative control and treated sample. 
 
Table 1. NMR Spectroscopic Data (500 and 700 MHz, DMSO) for 3,3′-Dihydroxy-5,7,4′-
trimethoxy-6,8-C-dimethylflavone (29) 
position δC, type δH (J in Hz) HMBCa 
2 143.35, C   
3 138.49, C   
4 171.79, C   
5 155.28, C   
6 121.39, C   
7 160.96, C   
8 115.60, C   
9 153.47, C   
10 112.83, C   
1′ 124.33, C   
2′ 114.60, CH 7.70, s 2, 3′, 4′, 6′ 
3′ 146.79, C   
4′ 149.47, C   
5′ 112.43, CH 7.09, d (14) 1′, 3′, 4′ 
6′ 119.65, CH 7.68, d (14) 2, 2′, 4′ 
OH-3  9.43, s  
OCH3-5 61.47, 3.75, s 5 
CH3-6 9.17, 2.18, s 6, 5, 7 
OCH3-7 60.83, 3.74, s 7 
CH3-8 9.43, 2.39, s 7, 8, 9 
OH-3′  9.10, s  
OCH3-4′ 56.02, 3.81, s 4′ 
a HMBC correlations are from the proton(s) stated to the indicated carbon. 
 
Combination Assays 
 
Extracts were tested in combination with berberine over a concentration range of 2.3 to 150 
μg/mL. Berberine alone served as a positive control and demonstrated an MIC value between 75 
and 150 μg/mL, consistent with the literature.(5) The vehicle consisted of 2% glycerol and 2% 
DMSO in broth. A simplified version of the synergy assay was performed after each stage of 
fractionation to quickly assess those fractions possessing additive and/or synergistic behavior. 
This involved testing berberine at a range of concentrations (2.3 to 150 μg/mL) in combination 
with a constant concentration of each of the extract fractions (75 μg/mL) or purified 
compound 29 (200 μM). The known efflux pump inhibitor piperine (75 μg/mL or 240 μM) was 
used as the positive control for these experiments.(38,47) Fractions were classified as active if 
they enhanced the antimicrobial activity of berberine (lowered the MIC by 2-fold) and were 
advanced to the next stage of separation. 
 
Biochemometric Analysis 
 
LC-MS data sets were collected in positive and negative polarities and were analyzed, aligned, 
and filtered in independent batches using MZmine 2.17 software 
(http://mzmine.sourceforge.net/),(48) as previously described by Kellogg et al.(12) Briefly, raw 
data files were uploaded into MZmine for peak picking based upon mass spectral signals that 
were above the signal intensity of a mass spectrometric chromatogram of an injection of 1:1 
MeOH–dioxane (solvent blank). Chromatograms were built based upon having a signal that 
lasted for longer than 0.01 min, minimum peak duration of 1.8 s (0.03 min), m/z variation 
tolerance of 0.05, and a m/z intensity variation tolerance of 20%. Peak list filtering and retention 
time alignment were also performed, and the join align algorithm compiled the final peak list. 
The mass spectral data matrix was exported into Excel (Microsoft, Redmond, WA, USA) where 
ions in common between the samples and solvent blank were manually removed from the sample 
mass spectral profiles, positive and negative polarity data sets were combined, and biological 
assay data were added in the form of MIC values of berberine in combination with certain 
fractions. Data matrices for each stage of fractionation were independently imported into Sirius 
version 10.0 (Pattern Recognition Systems AS, Bergen, Norway).(49) An internally cross-
validated PLS model of 100 iterations with a significance threshold set to 0.05 was constructed, 
and selectivity ratios were calculated using the Sirius software.(50) 
 
Supporting Information 
 
The Supporting Information is found at the end of this formatted article. 
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Figure S1.  Fractionation scheme. 
 
Figure S2.  Minimum inhibitory concentration (MIC) curves for berberine in combination with a constant concentration of fraction (75 µg/mL).  Each point 
represents the average OD600 of three wells with identical treatments, and error bars represent standard error of those measurements. 
 
Figure S3. 
1
H NMR (DMSO, 500 MHz) spectrum of 3,3´-dihydroxy- 5,7,4´ trimethoxy- 6,8-C-dimethyl-flavone (29). 
 
Figure S4. 
13
C NMR spectrum (DMSO 175 MHz) of 29. 
 
 
Figure S5. HSQC NMR spectrum of 29. 
 
Figure S6. HMBC NMR spectrum of 29. 
 
 
Figure S7. COSY NMR spectrum of 29.  
